The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
